EORTC QLQ-CX24: Quality of Life in Cervical Cancer
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Cervical Cancer Module · Also known as: QLQ-CX24
The EORTC QLQ-CX24 is a 24-item cervical-cancer-specific module designed to complement the EORTC QLQ-C30 core questionnaire. Developed by Greimel et al. in 2006, it measures sexual/vaginal function, body image, lymphedema, neuropathy, and gastrointestinal symptoms specific to cervical cancer and its treatments. It is the standard cervical cancer-specific QoL instrument in international oncology research.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
EORTC QLQ-CX24 is indicated for women with cervical cancer (any stage) undergoing surgery (hysterectomy, trachelectomy), pelvic radiation, chemotherapy, or surveillance. Primary use is clinical trials assessing treatment efficacy and patient-reported outcomes, particularly in gynecologic oncology research; secondary use in oncology clinic monitoring and supportive care research. NOT for screening or diagnosis. Particularly valuable when treatment decisions involve sexual/reproductive function trade-offs (e.g., radical hysterectomy vs. chemotherapy/radiation; fertility-sparing surgery options; adjuvant radiation impact).
Strengths & limitations
- Cervical-cancer-specific scales directly measure sexual/vaginal function, body image, and late toxicities (lymphedema, neuropathy)—critical domains in cervical cancer QoL not captured by generic scales.
- Validated in large cervical cancer populations across stages and treatment modalities (surgery, radiation, chemotherapy).
- Enables assessment of fertility and sexual function impact—particularly relevant in younger cervical cancer patients.
- Detailed symptom coverage (lymphedema, neuropathy, GI, menopausal) reflects cervical-cancer-specific late toxicities.
- Translated into 40+ languages; international standard in cervical cancer research.
- Relatively long module (24 items) when added to QLQ-C30 (54 items total); respondent burden may be high.
- Sexual/Vaginal Functioning scale (6 items) may lack detail for distinguishing specific sexual dysfunctions (dyspareunia vs. anorgasmia vs. loss of desire).
- Lymphedema and neuropathy items are symptom presence/severity scales, not objective measures of limb volume or neurophysiologic function.
- Limited validation in non-epithelial cervical cancers (adenocarcinoma, neuroendocrine) or metastatic disease.
Frequently asked
Is QLQ-CX24 appropriate for young cervical cancer survivors with fertility concerns?
Yes. QLQ-CX24 is validated across cervical cancer age groups, including young women (20s-40s). Sexual/Vaginal Functioning scale captures reproductive/sexual impact. However, QLQ-CX24 does not specifically assess fertility outcomes or reproductive planning. Supplement with fertility-specific questions or oncofertility counseling for comprehensive reproductive health assessment.
How does QLQ-CX24 compare to other gynecologic cancer QoL instruments?
EORTC QLQ-CX24 is cervical-cancer-specific. EORTC QLQ-OV28 (ovarian cancer) and QLQ-EN24 (endometrial cancer) exist for other gynecologic malignancies, each with disease-specific item focus. QLQ-CX24 is the standard for cervical cancer; do not use for other gynecologic cancers without validation.
What is the MCID for QLQ-CX24 scales?
MCID for QLQ-CX24 scales is approximately 10–15 points on 0–100 range. However, MCID may vary by scale; sexual/vaginal function may have different meaningful thresholds than symptom scales. In trials, MCID helps determine clinical significance of treatment-related changes.
Can QLQ-CX24 be used in patients undergoing fertility-sparing surgery (trachelectomy)?
Yes. QLQ-CX24 is appropriate for all cervical cancer surgical approaches, including fertility-sparing trachelectomy. Sexual/vaginal functioning scores may differ between hysterectomy and trachelectomy cohorts; ensure adequate statistical power and stratification if comparing approaches.
How are missing data handled in QLQ-CX24 scoring?
EORTC scoring guidelines: if ≥50% of items in a scale are missing, do not score that scale. If <50% are missing, impute the mean of completed items. Sexual/Vaginal Functioning scale (6 items) should have low missing rates; if significant missing data, consider whether respondents declined due to discomfort and use sensitivity analysis.
Is QLQ-CX24 freely available?
QLQ instruments are copyrighted by EORTC but available for non-commercial research use (registration required via qlg.eortc.be). Validated translations in 40+ languages are available through official channels. Use licensed versions to ensure psychometric validity.
Sources
- Greimel, E. R., Kuljanic Vlasic, K., Zwahlen, D., Rand, K., Heitz, U., Havsteen, H., et al. (2006). The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Acta Oncol, 45(3), 344–351. DOI: 10.1002/cncr.22217 ↗
- Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 85(5), 365–376. DOI: 10.1093/jnci/85.5.365 ↗
How to cite this page
ScholarGate. (2026, June 3). European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Cervical Cancer Module. ScholarGate. https://scholargate.app/en/oncology/eortc-qlq-cx24
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Cancer Worry ScaleOncology↔ compare
- EORTC QLQ-BR23Oncology↔ compare
- EORTC QLQ-C15-PALOncology↔ compare
- EORTC QLQ-LC13Oncology↔ compare
- FACT-OvarianOncology↔ compare